Core Viewpoint - The study reveals that the natural small molecule Lawsone, derived from the plant Impatiens, can enhance the antitumor activity and stem-like properties of CD8⁺ T cells by modulating the NQO1 enzyme and driving metabolic reprogramming through the pentose phosphate pathway (PPP) [2][3][12]. Group 1: Mechanism of Action - Lawsone hijacks the NQO1 enzyme in T cells, inducing redox cycling that enhances the PPP, thereby conferring unique stem-like properties and mitochondrial adaptability to effector CD8⁺ T cells [3][10]. - The Law-NQO1 signaling axis exhibits a biphasic regulation pattern: initially amplifying PPP activity and mROS levels to drive T cell differentiation, followed by a sustained phase that enhances cell proliferation and maintains stemness [10][14]. Group 2: Clinical Implications - The strategy shows strong clinical translation potential, as simple pharmacological pre-treatment of tumor-specific T cells with Lawsone significantly improves their tumor-killing efficiency and persistence in vivo without notable systemic toxicity [12][15]. - This research highlights NQO1 as a new immune metabolic checkpoint and provides a straightforward, cost-effective optimization strategy for T cell therapy without complex genetic modifications [15].